Age-related differences in cancer relative survival in the US: a SEER-18 analysis

Diana R Withrow, PhD, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

Brian D Nicholson, MRCGP, DPhil, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

Eva JA Morris, PhD, Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, UK

Melisa L Wong, MD, MAS Divisions of Hematology/Oncology and Geriatrics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA

Sophie Pilleron*, PhD, Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, UK

* Corresponding author

Richard Doll Building, Old Road Campus

Oxford UK

OX3 7LF

Tel: 44(0)1865 743743

sophie.pilleron@ndph.ox.ac.uk; sophie.pilleron@gmail.com

Word count: 2724 (limit 3000)

Key Points (100 words)

Question: After accounting for background differences in mortality, how big are differences in one-year cancer survival between older and younger adults and how does the magnitude vary by cancer site and stage?

Findings: In this analysis of population-based cancer registry data, age-related differences in cancer survival varied widely, ranging from less than 1% absolute difference in localized breast and prostate cancer survival to over 30% absolute difference in localized pancreatic cancer survival.

Meaning: Focused efforts to reduce age-related differences in cancer survival may have greatest impact by prioritizing cancer site and stage combinations with the widest differences.

Abstract

Importance: In the United States (US) in 2017, nearly half a million adults aged 75 and older were diagnosed with cancer. Cancer survival has improved since the 1990s, but to different extents across age groups, with a disadvantage for older adults. Documenting age-related differences in cancer survival in the US can help to inform prioritization efforts to narrow the age-related gap in cancer survival.

Objective: To quantify age-related differences in relative survival by stage at diagnosis for 10 cancer types.

Design: Retrospective population-based observational study of cancers diagnosed between 2012-2016 with follow-up through December 31, 2017

Setting: 18 US Surveillance Epidemiology and End Results cancer registries

Participants: 844,296 individuals aged 50 and over with first primary cancers of the prostate, breast, rectum, colon, ovary, esophagus, stomach, liver, lung, and pancreas.

Exposure: Age at cancer diagnosis (50-64, 65-74, 75-84, 85-99) and stage at diagnosis (localized, regional, distant, and unknown/unstaged).

Main Outcome(s) and Measure(s): One-year relative survival (RS). We estimated the absolute difference in 1-year RS between the 50 to 64 age group and the 75 to 84 age group.

Results: The smallest age-related differences were observed for prostate and breast cancers (1.8%-points [95% confidence interval (CI): 1.5-2.1] and 1.9%-points [95% CI: 1.5-2.3], respectively). The largest was for ovarian cancer (27 points, 95%CI: 24-29). For other cancers, differences ranged between 7 (95% CI: 5-9, esophagus) and 18%-points (95% CI: 17-19, pancreas). With the exception of pancreatic cancer, cancer type and stage combinations with either very high (e.g., >95%) or very low (e.g., <40%) 1-year RS tended to have smaller age-related differences in survival than those with mid-range prognoses.

Conclusions and Relevance: The broad age-related variation in survival across cancer types and stages may reflect the degree to which cancers are amenable to anti-cancer treatment. Future work to measure the extent of age-related differences that are avoidable, and identify how to narrow the survival gap, may have most benefit by prioritizing cancers with relatively large age-related differences in survival, especially at earlier stages (e.g., stomach, esophagus, liver and pancreas).

Introduction

In the United States (US) in 2017, nearly half a million adults aged 75 and over were diagnosed with cancer,[1] and around 260,000 cancer deaths occurred in the same age group.[2] As the US population ages, more cancer cases and deaths will occur in older individuals.[3]

The International Cancer Benchmarking Project (ICBP) study in seven high-income countries with similar health care systems (excluding the US) recently showed that cancer survival has improved since the 1990s, but not similarly across age groups and cancer types. Even after taking into consideration differences in life expectancy, older adults have experienced smaller improvements in survival than younger people resulting in widening differences in cancer survival across age groups.[4,5] Outside ICBP countries, the magnitude and pattern of age-related differences in cancer survival are poorly documented.

Up-to-date information about the pattern of age-related gaps in cancer survival is required to motivate and direct efforts to understand and, hence, improve cancer outcomes for older adults. Stage is an important predictor of survival, but among those studies that have measured age-related differences in cancer survival,[5-11] those that have stratified by stage tend to be focused on a single cancer type.[8-11] Comparing patterns in age-related differences in relative survival by stage across multiple cancer types with different prognoses, however, can provide insight and generate hypotheses as to how age-related differences in survival arise.

In this study, we describe age-related differences in 1-year relative survival (RS) by stage across 10 cancer sites, namely, prostate, breast, rectum, colon, ovary, esophagus, stomach, liver, lung, and pancreas in adults aged over 50 years. RS is a measure of net survival, that is a cancer survival in the absence of other causes of death. Together, these ten cancer sites accounted for nearly 60 percent of all cancers diagnosed in US adults aged 50 and older in 2016.

Methods

Data Source

We included all first primary prostate, breast, rectum, colon, ovary, esophagus, stomach, liver, lung, and pancreas cancers diagnosed between 2012 and 2016 from 18 US Surveillance Epidemiology and End Results (SEER) cancer registries and followed for vital status through December 2017. The 18 SEER registries are located in California (San Francisco/Oakland, San Jose/Monterey, Los Angeles, Greater California), Connecticut, the Detroit metropolitan area, Hawaii, Iowa, New Mexico, Seattle, Utah, Georgia (Atlanta, rural Georgia and Greater Georgia), Alaska (restricted to Alaska Natives), Kentucky, Louisiana, and New Jersey.[12,13] Together, these population-based registries cover nearly 30% of the US population.[12]

Seven of the included cancer sites were chosen to be comparable with the ICBP study results.[4] Prostate, breast and liver cancers were added due to their high contribution to cancer incidence and mortality. Because of their high survival and use of surgery as a primary treatment modality, breast and prostate cancers also provide an interesting contrast to the other cancers included from which to generate hypotheses about drivers of age differences.

Cancers were originally coded using ICD-O-3 and grouped according to the SEER ICD-O-3/WHO 2008 definitions.[14] As our primary interest was in age-related differences in survival, we included only cases diagnosed in patients aged over 50. We excluded cancers that were registered based on death certificate or autopsy only (1.5%), were non-malignant (6.4%), were missing age (0.04%), or with disagreement between vital status and survival time (0.4%).

Statistical analysis

We estimated 1-year RS using the Ederer II method. Relative survival is a metric of net survival, which estimates the probability of survival from cancer in the absence of other

causes of death. It is especially useful for comparing survival between groups for whom background mortality differs since it is estimated based on the ratio of the observed survival to the expected survival of individuals of similar demographics in the general population.[15,16]

Expected mortality was estimated from life tables stratified by county, age, year, sex, race/ethnicity and county-level socioeconomic status (SES) index.[17] The SES index is a composite variable based on seven county-level SES attributes collected by the American Community Survey.[18]

RS estimates were stratified by age (50-64, 65-74, 75-84, and 85-99 years), and stage (SEER Summary Stage, categorized as localized, regional, distant, and unknown/unstaged).[19] We excluded patients aged 100+ as expected life tables extend only to age 99.[20] Age-related differences in 1-year RS were assessed using the absolute differences in RS between the 50 to 64 age group and the 75 to 84 age group. We estimated 95% confidence interval around differences of RS using Monte Carlo simulations assuming the complementary log-log transformed RS values to be normally distributed. For each difference considered, the confidence limits were obtained by taking the 2.5 and 97.5 percentiles of the empirical RS difference distribution resulting from 100,000 random draws in the complementary log-log transformed RS values distribution.

If improvements in cancer survival are to be made, they are more likely to be observed at a population level among patients aged 75 to 84 compared to those 85 to 99. Therefore, the 75 to 84 age group was used as reference to calculate absolute differences in survival.

SEER data are publicly available and therefore ethics approval was not required. Data and relative survival estimates were retrieved through SEER*Stat software version 8.3.9 (National Cancer Institute). Data analysis was conducted between June and August 2021 by DW and SP. The estimation of confidence intervals around differences and plotting

of results were performed using R statistical software (version 4.0.2; R Development Core Team, 2020).

Results

We included a total of 844 296 people diagnosed with cancer between the ages of 50 to 99 between 2012 and 2016. Figure 1 presents the distribution of stage at diagnosis by age groups for the ten cancer sites. Over half of prostate and breast cancers and about half of liver cancers were diagnosed at localized stage while less than a quarter of ovarian, esophageal, lung and pancreatic cancers were diagnosed early. The proportion of cancers of unknown stage increased after the age of 75 and was largest in the group aged 85 to 99, with percentages ranging from 6% for breast cancer to 29% for esophageal cancer in this age group.

Overall

One-year RS estimates were highest for prostate and breast cancers (>80% across age groups) and lowest for pancreatic cancer (43% in 50 to 64 age group and 25% in 75 to 84 age group, Table 1). Prostate, breast, colon, rectal and ovarian cancers all had relatively good prognosis in the youngest age group (1-year RS ≥86% in persons aged 50 to 64 years) whereas stomach, esophageal, liver, lung, and pancreatic cancers had relatively poor prognosis (42% to 63% in persons aged 50 to 64 years). For localized and regional prostate and breast cancers, 1-year RS remained high (>95%) until age 85, whereas survival for other cancer sites tended to decrease with increasing age. For unknown/unstaged cancers, 1-year RS fell between the RS observed for regional and distant stages, except for ovarian cancer for which unknown cancers had poorer RS than distant cancers.

The smallest absolute difference in 1-year RS between the 50 to 64 age group and 75 to 84 age group was observed for prostate and breast cancers with a difference of 1.8 percentage points (95% confidence interval [CI] for prostate: 1.5-2.1), and 1.9 percentage points (95% CI breast: 1.6-2.3), respectively, and the largest was for ovarian cancer with a

27 percentage point difference (95% CI: 25-28, 1-year RS = 86% in the 50 to 64 age group vs. 59% in the 75 to 84 age group). The age-related differences in 1-year RS for other cancers ranged from 7 percentage points for esophageal cancer (95% CI: 5-9) to 18 percentage points for pancreatic cancer (95% CI: 17-19).

Stage-specific differences (Table 1, Figure 2)

Overall, age-related differences in 1-year RS increased with worsening stage for the better prognosis cancer types (i.e., those with overall 1-year RS exceeding 85%: prostate, breast, colon, rectum, and ovary), while the opposite was observed for all the remaining cancers except stomach cancer. For stomach cancer, age-related differences remained relatively consistent irrespective of stage.

For localized cancers, the biggest age-related difference in 1-year RS was seen for pancreatic cancer with a difference of over 35 percentage points (95% CI: 32-39) between RS in the 50 to 64 age group (78%) and the 75 to 84 age group (43%). For localized prostate and breast cancers, the age-related difference was negligible.

For regional cancers, age-related differences in 1-year RS were greatest for pancreatic cancer (21 percentage point difference, 95% CI: 19-23) and ovarian cancer (20, 95% CI: 16-25). Differences ranged between 9 and 16 percentage points for stomach, esophagus, liver, and lung cancers.

For distant cancers, the greatest age-related differences in 1-year RS were observed for colon and rectal cancers with differences of 28 (95% CI: 26-30) and 27 (95% CI: 23-31) percentage points respectively, closely followed by ovarian cancer with a difference of 23 points (95% CI: 21-25). For distant liver cancer, there was no difference in survival by age (1-year RS = 14% in 50 to 64 age group and 75 to 84 age group).

For cancers of unknown stage, the age-related difference in 1-year RS ranged between 6 (prostate cancer, 95% CI: 5-8) and 37 percentage points (colon cancer, 95% CI: 32-41).

Discussion

Using high-quality data from 18 SEER population-based cancer registries, we described overall and stage-specific age-related differences in 1-year RS for 10 cancer types. For some cancers with overall very good prognoses (e.g., localized breast and prostate cancers, 1-year RS >95% for adults aged 50-84) or very poor prognoses (distant stage esophageal and liver cancers, 1-year RS <40%), age-related differences in RS were negligible. Age-related differences were largest for localized pancreatic cancer and unknown stage rectal, colon and ovarian cancers. This broad age-related variation by prognosis (i.e., cancer type and/or stage) suggests that age-related differences may depend on the extent that cancers are amenable to treatment.

Our results add to the growing international body of work that describes age-related differences in cancer survival.[6,7,9,21] Whereas other studies commonly adjust for age at diagnosis, we considered age at diagnosis as an independent axis of investigation. Without measuring age-related differences directly, Zeng et al. reported that improvements in cancer survival between 1990 and 2009 in the US were significantly larger for younger patients with cancer, and that this was particularly the case for colorectal, breast, and early stage liver cancers.[5] The magnitude of the differences reported here are smaller than those reported for cases diagnosed in France between 1989 and 1997,[6] but similar to those reported for a pooled European analysis of cases from 2000 to 2002.[7] The ICBP study compared survival among persons by age splitting at age 75 for all stages combined and, like this study in the US, found large age-related differences in survival for ovarian and pancreatic cancers, but the rank order of cancers by age-related difference varied across countries. Age-related differences in lung cancer survival were high in New Zealand and Norway, for example, and age-related differences in esophageal cancer survival were higher in Ireland and Norway. With respect to stage, in New Zealand, authors found greater age-related differences in colon cancer survival with worsening stage at diagnosis,[16] and age-related in differences in lung cancer survival were higher for regional vs. advanced disease,[9] both patterns being

consistent with our results. Given differences in health care systems internationally and potential differences in data quality, collection, and analytical methods, the exact magnitude of age-related differences are difficult to compare.

We observed that when diagnosed early with relatively good prognosis cancers (e.g., localized and regional stage prostate and breast cancers, and localized colorectal and ovarian cancers) or with late-stage poor prognosis cancer (e.g., liver), older adults have similar survival probabilities (when considering differences in life expectancy) as their younger peers. If treatment is a primary driver of age-related difference in cancer survival, our results would suggest equally tolerated treatment regimens across age groups for the diagnoses with better prognoses. For diagnoses with poorer prognoses, the small differences observed across age groups are likely to be explained by their high lethality regardless of patients' age.

Age-related differences in RS were greater in good prognosis cancers diagnosed at later stage (e.g., colon or rectal cancers) and poor prognosis cancers diagnosed at early stage (e.g., pancreatic, esophageal, or liver cancers). This observation may be explained by several factors. First, different treatment strategies may be offered or accepted in younger and older patients because of differences in health status or patients' preferences. Older adults may be less likely to receive curative treatment,[22-28] and especially in the face of uncertain prognosis, may be more likely to value quality of life over survival.[29] Second, in the context of a poor evidence base on treatment strategies in older adults,[30] the effectiveness and toxicity of treatment may differ across age groups. Evidence suggests higher post-treatment mortality and increased all-cause mortality in older patients, particularly in frailer ones.[31]

Factors other than treatment could also contribute to the age-related differences in cancer survival reported here, such as tumor-specific factors. For example, age-related differences in lung cancer survival have been shown to vary by histology, and by subsite in colorectal cancer.[16] It is also possible that insurance status or more generally access to care

may affect age-related differences in survival. Future research should continue to disentangle the role of these factors on age-related differences across a range of cancer types.

As is apparent from Figure 1, age is associated with higher likelihood of having an unstaged cancer.[32] We observed large age-related differences in cancer survival for colon, rectal, ovarian and stomach cancers of unknown stage. Cancers will have unknown stage if there were insufficient information for the registry to assign stage or may reflect a decision not to pursue a staging workup if the potential harms outweigh the benefits (i.e., due to patient preference, or if the patient is too frail for cancer treatment regardless of stage). In the absence of reasons for missingness and how they vary by age, it is difficult to explain age-related differences in cancer survival for cancer of unknown stage in our study. For example, if all younger patients had missing stage due to data collection errors and all older patients had cancer of unknown stage because it was not investigated (poor health status or patient preferences), the differences in survival between them would be inappropriate to interpret since they represent different types of patients or cancers. While the determinants of unstaged disease have been explored and age has been determined as a primary factor,[33-35] the determinants of missingness within age categories, and how they differ by age have not been documented and are worthy of future research in order to better interpret results of studies like this one.

This study has limitations, largely as a consequence of its broad scope. Our multi-cancer approach and use of cancer registry data prohibited a detailed analysis of the influence of specific patient, tumor, and/or healthcare system factors that could also explain age-related differences in survival. For example, because of the lack of information about comorbidity, frailty, or other geriatric conditions, it was not possible to distinguish fit versus frail patients. Consequently, we were unable to disentangle which share of the age-related differences in survival observed may be avoidable versus arose as a consequence of differences in baseline health status. Despite these limitations, the paper provides insight on

the role of stage in age-related disparities and how this varies by cancer type, knowledge which can be mobilized to priority efforts to narrow age gaps in survival.

With respect to methods, the estimation of relative survival relies on background mortality rates obtained from lifetables and implies that in the absence of cancer, people in our study cohort would have the same mortality risk as the general population. While the US life tables account for differences in age, sex, ethnicity and county SES between cancer patients and the general population, they are not specific to other factors influencing prognosis and mortality (such as comorbidities and smoking), for which the prevalence may differ between cancer patients and the general population. Consequently, age-related differences in relative survival estimates may be underestimated.[36] In a recent study describing age-related differences in lung cancer survival, correction of life tables for smoking did change net survival estimates, but did not meaningfully change age-related differences in survival,[9] our main outcome of interest in the present study.

In this population-based study, we confirmed that cancer survival in older adults tends to be poorer even after accounting for differences in background mortality for a range of common cancers and we illustrated that the patterns of age-related differences varied by cancer type and stage and aligning with prognosis. More detailed studies of the determinants of age-related differences in cancer survival, taking into account characteristics of the patients, their cancers, and their treatment, are necessary to achieve better outcomes in older adults.

Acknowledgment

Authors thank Dr Hadrien Charvat for his guidance regarding calculating 95% confidence interval around differences in relative survival.

TABLES

Table 1. One-year relative survival from cancer by type, stage, and age. Survival differences between those aged 75 to 84 and aged 50 to 64. SEER18 registries, diagnosed 2012 to 2016. Continued on next page.

			Prostate		Breast		Rectum
	Age group	**n**	**Relative Survival% (95%CI)**	**n**	**Relative Survival% (95%CI)**	**n**	**Relative Survival% (95%CI)**
	50-64 years	91 559	99.7% (99.6; 99.8)	100 570	98.0% (97.9; 98.1)	16 043	92.3% (91.8; 92.7)
	65-74 years	89 079	100.0% (-; -)	61 655	97.8% (97.7; 98.0)	7 653	87.6% (86.8; 88.4)
Overall	75-84 years	31 104	97.9% (97.6; 98.2)	30 629	96.1% (95.8; 96.4)	4 233	78.9% (77.5; 80.3)
	85+ years	7 381	82.9% (81.7; 84.1)	11 588	90.8% (89.9; 91.6)	1 814	65.0% (62.3; 67.5)
	Survival difference		1.8 (1.5; 2.1)		1.9 (1.6; 2.3)		13.3 (11.9; 14.8)
	50-64 years	68 897	100.5% (-; -)*	63 467	100.0% (92.0; 100.0)	7 134	98.5% (98.1; 98.8)
	65-74 years	68 047	101.2% (-; -)*	42 676	100.3% (-; -)*	3 208	96.6% (95.7; 97.3)
Localized	75-84 years	22 444	102.4% (-; -)*	20 636	101.0% (-; -)*	1 648	92.2% (90.4; 93.7)
	85+ years	3 316	100.8% (-; -)*	6 794	101.6% (-; -)*	662	84.3% (80.0; 87.7)
	Survival difference		-1.9 (-; -)*		-1.0 (-; -)*		6.3 (4.8; 8.1)
	50-64 years	15 103	100.6% (-; -)*	30 093	98.7% (98.5; 98.8)	5 366	95.9% (95.2; 96.4)
	65-74 years	12 051	101.3% (-; -)*	14 878	98.3% (98.0; 98.5)	2 680	92.2% (90.9; 93.2)
Regional	75-84 years	2 102	99.9% (0; 100.0)	7 269	95.6% (94.8; 96.2)	1 479	86.9% (84.8; 88.8)
	85+ years	417	91.6% (85.6; 95.2)	3 035	91.2% (89.5; 92.7)	502	77.7% (72.6; 81.9)
	Survival difference		0.7 (-; -)		3.1 (2.5; 3.9)		8.9 (7.0; 11.2)
	50-64 years	4 328	84.8% (83.7; 85.9)	5 875	74.7% (73.6; 75.8)	2 652	69.4% (67.6; 71.2)
	65-74 years	4 797	82.4% (81.2; 83.6)	3 365	67.6% (65.9; 69.1)	1 352	60.7% (57.9; 63.3)
Distant	75-84 years	3 928	74.8% (73.3; 76.3)	2 150	58.2% (56.0; 60.3)	756	42.6% (38.9; 46.3)
	85+ years	2 334	63.0% (60.6; 65.3)	1 019	44.1% (40.8; 47.5)	330	28.1% (22.9; 33.4)
	Survival difference		10.0 (8.1; 11.9)		16.5 (14.1; 19.0)		26.8 (22.7; 30.9)
	50-64 years	3 231	98.7% (98.1; 99.1)	1 135	89.3% (87.2; 91.0)	891	89.0% (86.7; 91.0)
	65-74 years	4 184	97.3% (96.6; 97.9)	736	83.9% (80.9; 86.5)	413	77.2% (72.6; 81.1)
Unknown/unstaged	75-84 years	2 630	92.3% (90.8; 93.5)	574	68.7% (64.4; 72.5)	350	60.8% (55.1; 66.0)
	85+ years	1 314	70.3% (67.1; 73.3)	740	54.0% (49.8; 58.1)	320	43.0% (36.8; 49.1)
	Survival difference		6.4 (5.1; 8)		20.6 (16.3; 25.2)		28.2 (22.5; 34.2)

	Age group	n	Colon Relative Survival% (95%CI)	n	Ovary Relative Survival% (95%CI)	n	Stomach Relative Survival% (95%CI)
Overall	50-64 years	30 171	87.9% (87.5; 88.2)	8 767	86.0% (85.2; 86.7)	8 671	63.4% (62.4; 64.4)
	65-74 years	21 822	83.7% (83.2; 84.2)	5 463	77.6% (76.4; 78.7)	7 068	61.4% (60.2; 62.6)
	75-84 years	16 264	74.9% (74.2; 75.6)	3 442	59.4% (57.7; 61.1)	5 442	52.2% (50.8; 53.6)
	85+ years	8 626	60.2% (59.0; 61.4)	1 610	32.2% (29.7; 34.6)	2 564	34.8% (32.8; 36.9)
	Survival difference		13.0 (12.1; 13.8)		26.5 (24.7; 28.4)		11.2 (9.5; 12.9)
Localized	50-64 years	11 505	98.5% (98.2; 98.8)	1 457	98.4% (97.5; 99.0)	2 245	91.9% (90.6; 93.0)
	65-74 years	8 681	96.6% (96.0; 97.0)	528	96.0% (93.5; 97.6)	2 057	88.8% (87.2; 90.2)
	75-84 years	6 251	92.3% (91.4; 93.1)	231	93.7% (88.2; 96.7)	1 723	78.3% (76.0; 80.3)
	85+ years	2 736	84.1% (82.1; 85.9)	92	71.8% (58.9; 81.3)	820	55.7% (51.8; 59.5)
	Survival difference		6.2 (5.3; 7.1)		4.7 (1.6; 10.2)		13.6 (11.2; 16.1)
Regional	50-64 years	10 463	95.5% (95.0; 95.9)	2 092	94.3% (93.2; 95.3)	2 315	78.5% (76.7; 80.1)
	65-74 years	7 661	91.3% (90.6; 92.0)	968	88.6% (86.3; 90.6)	2 023	72.4% (70.3; 74.4)
	75-84 years	5 832	84.6% (83.4; 85.6)	487	74.2% (69.7; 78.1)	1 386	62.3% (59.5; 64.9)
	85+ years	2 923	75.2% (73.2; 77.1)	180	52.6% (44.2; 60.4)	442	48.1% (42.9; 53.2)
	Survival difference		10.9 (9.8; 12.1)		20.2 (16.1; 24.8)		16.2 (13.0; 19.5)
Distant	50-64 years	7 368	61.9% (60.8; 63.0)	4 961	79.9% (78.8; 81.0)	3 558	35.5% (33.9; 37.1)
	65-74 years	4 775	51.4% (49.9; 52.8)	3 741	73.5% (72.0; 74.9)	2 491	32.1% (30.2; 34.0)
	75-84 years	3 303	34.2% (32.6; 35.9)	2 461	56.8% (54.7; 58.8)	1 691	23.7% (21.6; 25.8)
	85+ years	1 749	19.9% (17.9; 21.9)	1 026	29.5% (26.5; 32.5)	654	10.1% (7.8; 12.8)
	Survival difference		27.7 (25.7; 29.7)		23.2 (20.8; 25.5)		11.8 (9.1; 14.4)
Unknown/unstaged	50-64 years	835	77.0% (73.9; 79.8)	257	64.9% (58.6; 70.4)	553	64.8% (60.5; 68.7)
	65-74 years	705	63.0% (59.2; 66.5)	226	55.2% (48.3; 61.5)	497	50.3% (45.7; 54.8)
	75-84 years	878	40.2% (36.8; 43.5)	263	27.3% (21.8; 33.0)	642	35.5% (31.7; 39.4)
	85+ years	1 218	28.9% (26.1; 31.7)	312	17.6% (13.3; 22.4)	648	24.1% (20.6; 27.8)
	Survival difference		36.8 (32.2; 41.2)		37.6 (29.2; 45.4)		29.2 (23.5; 34.7)

	Age group	Esophagus		Liver		Lung		Pancreas	
		n	Relative Survival% (95%CI)	n	Relative Survival% (95%CI)	n	Relative Survival% (95%CI)	n	Relative Survival% (95%CI)
Overall	50-64 years	5 870	52.0% (50.7; 53.3)	16 863	51.7% (50.9; 52.5)	56 724	51.1% (50.7; 51.5)	14 936	42.8% (41.9; 43.5)
	65-74 years	4 918	53.9% (52.4; 55.3)	8 871	51.2% (50.2; 52.3)	63 421	49.9% (49.5; 50.3)	14 082	35.9% (35.1; 36.8)
	75-84 years	2 848	45.1% (43.1; 47.0)	4 340	41.1% (39.5; 42.6)	44 942	42.8% (42.4; 43.3)	10 454	25.1% (24.2; 25.9)
	85+ years	1 071	27.4% (24.5; 30.4)	1 391	26.8% (24.3; 29.3)	15 068	30.3% (29.5; 31.1)	5 279	12.4% (11.5; 13.4)
	Survival difference		6.9 (4.6; 9.2)		10.6 (9.0; 12.4)		8.3 (7.6; 8.9)		17.7 (16.5; 18.9)
Localized	50-64 years	906	80.0% (77.1; 82.5)	8 217	72.9% (71.9; 73.9)	8 151	90.7% (90.; 91.3)	1 427	78.4% (76.1; 80.5)
	65-74 years	900	76.8% (73.8; 79.6)	4 326	71.8% (70.3; 73.1)	11 976	88.0% (87.4; 88.7)	1 251	65.5% (62.7; 68.1)
	75-84 years	621	64.1% (59.9; 68.0)	1 983	60.0% (57.6; 62.2)	8 944	82.3% (81.4; 83.2)	1 279	43.0% (40.2; 45.8)
	85+ years	245	45.0% (37.9; 51.9)	553	47.3% (42.7; 51.9)	2 629	71.7% (69.6; 73.7)	879	26.8% (23.6; 30.0)
	Survival difference		15.9 (11.1; 20.8)		12.9 (10.5; 15.5)		8.4 (7.3; 9.5)		35.4 (31.8; 39.0)
Regional	50-64 years	2 011	67.3% (65.2; 69.3)	4 547	41.5% (40.0; 43.0)	12 510	73.0% (72.2; 73.8)	4 689	64.0% (62.6; 65.4)
	65-74 years	1 747	66.9% (64.6; 69.2)	2 354	41.0% (39.0; 43.0)	14 646	69.0% (68.2; 69.7)	4 506	56.3% (54.8; 57.8)
	75-84 years	915	57.9% (54.4; 61.2)	1 081	32.7% (29.8; 35.6)	9 755	59.1% (58.1; 60.1)	3 090	42.9% (41.1; 44.8)
	85+ years	253	39.0% (32.3; 45.5)	280	16.0% (11.7; 20.8)	2 549	41.5% (39.3; 43.6)	1 043	19.7% (17.1; 22.3)
	Survival difference		9.4 (5.5; 13.4)		8.8 (5.5; 12.0)		13.9 (12.6; 15.2)		21.1 (18.8; 23.4)
Distant	50-64 years	2 585	31.7% (29.9; 33.5)	2 569	14.1% (12.8; 15.5)	34 761	34.3% (33.8; 34.8)	8 348	25.2% (24.3; 26.2)
	65-74 years	1 889	32.9% (30.8; 35.1)	1 313	16.3% (14.3; 18.4)	34 824	29.6% (29.1; 30.1)	7 719	20.3% (19.4; 21.2)
	75-84 years	951	24.7% (21.9; 27.6)	673	14.3% (11.7; 17.2)	23 923	23.1% (22.6; 23.6)	5 282	11.7% (10.8; 12.6)
	85+ years	267	12.0% (8.2; 16.6)	196	10.9% (6.8; 16.1)	8 060	15.3% (14.5; 16.2)	2 235	4.7% (3.8; 5.7)
	Survival difference		7.0 (3.6; 10.3)		-0.2 (-3.3; 2.8)		11.2 (10.4; 11.9)		13.6 (12.3; 14.8)
Unknown/unstaged	50-64 years	368	42.0% (36.9; 47.1)	1 530	30.9% (28.5; 33.2)	1 302	43.2% (40.5; 45.9)	472	33.9% (29.6; 38.2)
	65-74 years	382	43.9% (38.8; 49.0)	878	29.8% (26.8; 33.0)	1 975	34.3% (32.2; 36.4)	606	23.0% (19.7; 26.5)
	75-84 years	361	33.7% (28.6; 38.8)	603	23.6% (20.1; 27.1)	2 320	26.0% (24.1; 27.9)	803	15.6% (13.1; 18.3)
	85+ years	306	17.2% (12.8; 22.0)	362	12.5% (9.2; 16.4)	1 830	21.1% (19.1; 23.2)	1 122	9.8% (8.0; 11.8)
	Survival difference		8.4 (1.1; 15.5)		7.3 (3.1; 11.5)		17.2 (13.9; 20.5)		18.3 (13.2; 23.3)

CI: Confidence interval * Confidence intervals could not be computed because relative survival estimates are above 100%.

REFERENCES

1. United States Cancer Statistics - Incidence: 1999 - 2017, WONDER Online Database. Centers for Disease Control and Prevention and National Cancer Institute,; 2020 http://wonder.cdc.gov/cancer-v2017.html. Accessed August 17, 2021.
2. United States Cancer Statistics - Mortality: 1999 - 2017, WONDER Online Database Centers for Disease Control and Prevention; 2020. http://wonder.cdc.gov/CancerMort-v2017.html Accessed August 17 2021.
3. Colby S, Ortman JM. Projections of the size and composition of the US population: 2014 to 2060. In: US Department of Commerce, Economics and Statistics Administration, US …; 2015.
4. Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. *The Lancet Oncology.* 2019;20(11):1493-1505.
5. Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. *JAMA Oncol.* 2015;1(1):88-96.
6. Colonna M, Bossard N, Remontet L, Grosclaude P. Changes in the risk of death from cancer up to five years after diagnosis in elderly patients: a study of five common cancers. *International journal of cancer.* 2010;127(4):924-931.
7. Quaglia A, Tavilla A, Shack L, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. *European Journal of Cancer.* 2009;45(6):1006-1016.
8. Pilleron S, Charvat H, Araghi M, et al. Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. *International journal of cancer.* 2021;148(7):1575-1585.
9. Pilleron S, Maringe C, Charvat H, Atkinson J, Morris E, Sarfati D. Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors. *Lung Cancer.* 2021;157:92-99.
10. Pilleron S, Maringe C, Charvat H, Atkinson J, Morris EJA, Sarfati D. The impact of timely cancer diagnosis on age disparities in colon cancer survival. *J Geriatr Oncol.* 2021;12(7):1044-1051.
11. DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019. *CA Cancer J Clin.* 2019;69(6):452-467.
12. Surveillance E, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (2000-2016) <Katrina/Rita Population Adjustment>. In: National Cancer Institute D, Surveillance Research Program, ed. Rockville, MD2019.
13. Surveillance Epidemiology and End Results Program. SEER*Stat Databases: November 2018 Submission. National Cancer Institute, . https://seer.cancer.gov/data-software/documentation/seerstat/nov2018/. Published 2019. Accessed Dec 3 2019, 2019.
14. National Cancer Institute. ICCC Recode ICD-O-3/WHO 2008. https://seer.cancer.gov/iccc/iccc-who2008.html. Published 2008. Accessed 12/11/2017, 2017.
15. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. *Int J Epidemiol.* 2010;39(2):598-610.
16. Pilleron S, Gower H, Janssen-Heijnen M, et al. Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review. *BMJ Open.* 2021;11(3):e044239.
17. Mariotto AB, Zou Z, Johnson CJ, Scoppa S, Weir HK, Huang B. Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. *PLoS One.* 2018;13(7):e0201034.

18. Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. *Cancer Causes Control.* 2014;25(1):81-92.

19. Surveillance EaER. Localized/Regional/Distant Stage Adjustments. https://seer.cancer.gov/seerstat/variables/seer/yr1975_2017/lrd_stage/index.html. Published 2020. Accessed.

20. US National Cancer Institute SEaERP. Expected Survival Life Tables. https://seer.cancer.gov/expsurvival/. Published 2018. Accessed 2022-02-14, 2022.

21. Pilleron S, Maringe C, Charvat H, Atkinson J, Morris EJ, Sarfati D. The impact of timely cancer diagnosis on age disparities in colon cancer survival. *J Geriatr Oncol.* 2021.

22. Sarasqueta C, Perales A, Escobar A, et al. Impact of age on the use of adjuvant treatments in patients undergoing surgery for colorectal cancer: patients with stage III colon or stage II/III rectal cancer. *BMC cancer.* 2019;19(1):1-15.

23. Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. *Annals of Oncology.* 2018;29(2):377-385.

24. Limonnik V, Abel S, Finley GG, Long GS, Wegner RE. Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis. *Lung Cancer.* 2020;150:107-113.

25. Belot A, Fowler H, Njagi EN, et al. Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: a population-based study. *Thorax.* 2019;74(1):51-59.

26. Gooiker GA, Dekker JWT, Bastiaannet E, et al. Risk factors for excess mortality in the first year after curative surgery for colorectal cancer. *Annals of surgical oncology.* 2012;19(8):2428-2434.

27. Dekker JWT, van den Broek CB, Bastiaannet E, van de Geest LG, Tollenaar RA, Liefers G-J. Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. *Annals of surgical oncology.* 2011;18(6):1533-1539.

28. Majano SB, Di Girolamo C, Rachet B, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. *The lancet oncology.* 2019;20(1):74-87.

29. Seghers PA, Wiersma A, Festen S, et al. Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient—A Systematic Review. *Cancers.* 2022;14(5):1147.

30. Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. *CA: a cancer journal for clinicians.* 2021;71(1):78-92.

31. Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. *Annals of oncology.* 2015;26(6):1091-1101.

32. Herget K, Stroup A, Smith K, Wen M, Sweeney C. Unstaged cancer: long-term decline in incidence by site and by demographic and socioeconomic characteristics. *Cancer Causes & Control.* 2017;28(4):341-349.

33. Merrill RM, Sloan A, Anderson AE, Ryker K. Unstaged cancer in the United States: a population-based study. *BMC cancer.* 2011;11(1):1-10.

34. Koroukian SM, Xu F, Beaird H, Diaz M, Murray P, Rose JH. Complexity of care needs and unstaged cancer in elders: a population-based study. *Cancer detection and prevention.* 2007;31(3):199-206.

35. Di Girolamo C, Walters S, Benitez Majano S, et al. Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013. *BMC cancer.* 2018;18(1):1-10.

36. Blakely T, Soeberg M, Carter K, Costilla R, Atkinson J, Sarfati D. Bias in relative survival methods when using incorrect life-tables: Lung and bladder cancer by smoking status and ethnicity in New Zealand. *International journal of cancer.* 2012;131(6):E974-E982.

FIGURE TITLES

Figure 1. Distribution of stage at diagnosis by age groups and cancer types.

Figure 2. Absolute difference in relative survival between 50 to 64 year olds and 75 to 84 year olds by cancer site and stage.

FIGURE CAPTIONS

Figure 2: Note: Capped lines are 95% confidence intervals around difference